Eli Lilly’s head-to-head CHALLENGE-MIG trial missed its primary endpoint Friday, failing to establish the statistical superiority of the company’s Emgality (galcanezumab-gnlm) over Pfizer’s Nurtec orally disintegrating tablets (rimegepant).